The effects of low‐dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women

Buckler, Helen; McElhone, Kathleen; Durrington, Paul N.; Mackness, M. I.; Ludlam, C. A.; Wu, F. C. W.

doi:10.1046/j.1365-2265.1998.00525.x

Cited by 48 publications

(31 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Buckler et al treated 22 patients with severe premenstrual syndrome with 100 mg SC T implants every 6 months for a mean duration of 3.3 years and compared them with 22 age-matched control patients with severe premenstrual syndrome who had not received T therapy (51). Of interest, all patients continued to have regular menses.…”

Section: Lipidsmentioning

confidence: 98%

Safety of testosterone treatment in postmenopausal women

Braunstein¹

2007

Fertility and Sterility

View full text Add to dashboard Cite

Section: Lipidsmentioning

confidence: 98%

Safety of testosterone treatment in postmenopausal women

Braunstein¹

2007

Fertility and Sterility

View full text Add to dashboard Cite

“…The small number of participants and the lack of longer-term studies currently prevent proper evaluation of the effects of testosterone treatment on body composition, bone mineral density or insulin sensitivity. Study results showing androgen effects on lipids are also heterogeneous, but androgens are consistently reported to induce a decrease in high-density lipoprotein (HDL) cholesterol levels (29,32,33). Since early on, the effects of androgens on female sexuality have been the main focus of research.…”

Section: Clinical Experience With Testosterone Therapy In Womenmentioning

confidence: 99%

Androgen therapy in women

Arlt

2006

eur j endocrinol

105

View full text Add to dashboard Cite

Androgens in women either derive from direct ovarian production or from peripheral conversion of the adrenal sex steroid precursor, dehydroepiandrosterone, towards active androgens. Therefore, loss of adrenal or ovarian function, caused by Addison's disease or consequent to bilateral oophorectomy, results in severe androgen deficiency, clinically often associated with a loss of libido and energy. Importantly, physiological menopause does not necessarily lead to androgen deficiency, as androgen synthesis in the ovaries may persist despite the decline in estrogen production. However, the definition of female androgen deficiency, as recently provided by the Princeton consensus statement, is not precise enough and may lead to over-diagnosis due to the high prevalence of its diagnostic criteria: androgen levels below or within the lower quartile of the normal range and concurrent sexual dysfunction. Importantly, physiological menopause is not necessarily associated with androgen deficiency and therefore does not routinely require androgen therapy. Current replacement options include transdermal testosterone administration or dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements, in particular in libido and mood, while effects on body composition and muscular function are not well documented. It is important to keep in mind that the number of randomized controlled trials is still limited and that currently none of the available preparations is officially approved for use in women. Currently, androgen replacement should be reserved for women with severe androgen deficiency due to an established cause and matching clinical signs and symptoms.

show abstract

“…189) suggesting a positive effect of androgens on fibrinolysis. According to a more recent report, low dose androgen therapy has not been associated with any changes in clotting factor levels in women (32).…”

Section: Androgens and The Hemostatic Systemmentioning

confidence: 99%

Cardiovascular Effects of Androgens

Weidemann

Hanke

2002

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

In the process of atherosclerosis sex steroids play a complex role in the vascular vessel wall system. Although a number of experimental studies have clearly documented an atheroprotective effect of estrogens, in recent clinical studies, estrogen replacement therapy has failed to reduce cardiovascular mortality. The effects of androgens on the cardiovascular system and cardiovascular diseases are even more controversial. Whereas in the past, androgens were mainly believed to exert adverse effects on the cardiovascular system, recent studies in men have documented a number of beneficial actions of testosterone in the arterial vascular system. Androgens affect lipid metabolism (e.g., LDL and HDL cholesterol, Lp(a)) and hemostasis (e.g., platelet aggregation and fibrinolytic activity). In addition, several other physiological and pathophysiological processes in the arterial vessel wall are influenced by androgens. Acute hemodynamic effects of testosterone on coronary vasomotion and stress-test-induced ischemia were reported. Additionally, recent animal and in vitro studies have further documented an inhibitory effect of androgens on neointimal plaque formation. This review discusses different and, in part, contradictory effects of androgens on the cardiovascular system including potential signal transduction pathways in androgen target cells.

show abstract

The effects of low‐dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women

Cited by 48 publications

References 48 publications

Safety of testosterone treatment in postmenopausal women

Safety of testosterone treatment in postmenopausal women

Androgen therapy in women

Cardiovascular Effects of Androgens

Contact Info

Product

Resources

About